Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246613 | 0.81 | TAAR1 (0.44) | TDP1CES1NR1H2NR1H3MEN1 | |
| SCHEMBL10884978 | 0.80 | MEN1 (0.49) | ALDH1A1TSHRCYP2C19MEN1HTT | |
| SCHEMBL81124 | 0.72 | ALDH1A1 (0.44) | ALDH1A1TSHRCYP2C19TDP1CA2 | |
| SCHEMBL3736957 | 0.72 | ALDH1A1 (0.48) | ALDH1A1TSHRCYP2C19CA2CES1 | |
| SCHEMBL26802 | 0.72 | ALDH1A1 (0.48) | ALDH1A1TSHRTDP1CA2MEN1 | |
| SCHEMBL28570283 | 0.72 | ALDH1A1 (0.51) | ALDH1A1TSHRTDP1CA2MEN1 | |
| Hydrochloric Acid SCHEMBL4483825 | 0.70 | ALDH1A1 (0.46) | ALDH1A1TSHRCYP2C19CA2CES1 | |
| SCHEMBL20740838 | 0.70 | ALDH1A1 (0.46) | ALDH1A1TSHRCYP2C19CA2CES1 | |
| Hydrochloric Acid SCHEMBL12006735 | 0.70 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1CA2MEN1 | |
| Iodide SCHEMBL29093986 | 0.70 | ALDH1A1 (0.46) | ALDH1A1TSHRCYP2C19CA2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20100076084-A1 | Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes | GATLIN MARJORIE REGAN | 2010-03-25 | — | — | US | disclosed |
| US-20100029724-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-02-04 | — | — | US | disclosed |
| EP-2039779-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2011507-A2 | Pharmaceutical composition of nateglinide and another antidiabetic agent | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20070275928-A1 | METHOD OF TREATING METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES | GATLIN MARJORIE R | 2007-11-29 | — | — | US | disclosed |
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-20030162816-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | GATLIN MARJORIE REGAN (US) | 2003-08-28 | — | — | US | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-6559188-B1 | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes | NOVARTIS AG (CH) | 2003-05-06 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1212077-A2 | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETIC AGENT | Novartis AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001021159-A2 | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETCAGENT | NOVARTIS AG (CH) | 2001-03-29 | — | — | WO | disclosed |
| EP-0863881-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997010219-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029724-A1 | SCREENING METHOD | NR2C2, NCOR2, NCOA2 | ALDH1A1 3177/4885TSHR 163/4885CYP2C19 1595/4885 |
| US-20100076084-A1 | Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes | SLC2A2, TREH, GOT2 | ALDH1A1 452/4885TSHR 354/4885CYP2C19 1674/4885 |
| US-20070275928-A1 | METHOD OF TREATING METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETES | SLC2A2, TREH, GOT2 | ALDH1A1 452/4885TSHR 354/4885CYP2C19 1674/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | ALDH1A1 2652/4885TSHR 1173/4885CYP2C19 2178/4885 |
| US-20030162816-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | SLC2A2, SLC2A1, PPARD | ALDH1A1 214/4885TSHR 358/4885CYP2C19 2052/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | ALDH1A1 874/4885TSHR 2306/4885CYP2C19 2422/4885 |
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | ALDH1A1 1045/4885TSHR 534/4885CYP2C19 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.